James Howard Kunstler and I discuss COVID, what it would take to fix the practice of medicine, and other things
Hint: all the leverage to change medicine resides in the insurers, and Medicare could lead the way
Hint: all the leverage to change medicine resides in the insurers, and Medicare could lead the way
Rubberstamp the rollout of some terrible products, genuflecting to their betters, while putting their careers in jeopardy if the safety issues become known
Rubberstamp the rollout of some terrible products, genuflecting to their betters, while putting their careers in jeopardy if the safety issues become known
The risk of GOF was our risk, not his--no doubt he received the best countermeasures, while suppressing them for the public. Since he had already tested them.
The risk of GOF was our risk, not his–no doubt he received the best countermeasures, while suppressing them for the public. Since he had already tested them.
The official meetings for today ended a few minutes ago and will reconvene at 9:30 am Geneva time (3:30 am EDT)
The official meetings for today ended a few minutes ago and will reconvene at 9:30 am Geneva time (3:30 am EDT)
And much more, including economic info at the end of the interview
And much more, including economic info at the end of the interview
Original URL: https://merylnass.substack.com/p/peter-marks-head-of-vaccines-at-fda FDA authorized bivalent booster for 6 month olds after only a 3 day review of Pfizer documents Meryl Nass · December 8, 2022 Actually, FDA authorized both the Moderna and Pfizer bivalent boosters for kids 6 months through 5 years today. It had already authorized them for everyone else. Don’t expect the…